Thus, the ability of RASAL2 to target RAS and TNFα signal and inhibit the proliferative and invasive capacity of PCa cells indicates that restoration of RASAL2 expression or the use of synthetic or small molecule that can replace RASAL2 may be an attractive novel therapeutic approach that will not only target RAS oncogenic activity but can also immune signals in aggressive PCa treatment. The gene discussed is RASAL2; the disease is posterior cortical atrophy.